Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 18130
Corporate User License Price USD 750
Corporate User License Price INR 54390
Site License Price USD 500
Site License Price INR 36260
Request a Quote

Report Title

Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile



Executive Summary

Summary

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

Novartis AG, Medical Equipment, Deal Details 24

Asset Purchase 24

GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix for USD5 Million 24

Advanced Accelerator Applications to Acquire Two Production Sites in Germany 25

Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 26

SensoMotoric Sells Ophthalmic Division To Alcon Labs 27

Venture Financing 28

Pear Therapeutics Raises USD50 Million in Series B Financing 28

ImaginAb Raises USD7.7 Million in Venture Financing 30

Rani Therapeutics Raises USD39 Million in Series D Financing 31

Lemonaid Health Raises USD11 Million in Series A Financing 33

Atlas Genetics Raises USD35 Million in Series D Financing 34

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 36

Rox Medical Raises USD40 Million in Series E Financing 38

Cota Raises Funds through Venture Financing 39

Rani Therapeutics Raises Funds in Financing 40

Ra Pharma Raises USD58.5 Million in Series B Financing 42

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 44

MyoPowers Medical Raises USD5 Million in Venture Financing 46

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 47

Autonomic Technologies Raises USD38 Million in Series D Financing 48

Merganser Biotech Raises USD28 Million in Series A Financing 50

Encore Vision Raises USD1 Million in Venture Financing 51

Atlas Genetics Raises USD20 Million in Series C Financing 52

Transcend Medical Raises USD7.2 Million in Venture Financing 54

BioNano Genomics Raises USD53 Million in Series C Venture Financing 55

Encore Vision Raises USD1.7 Million in Venture Financing 57

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 58

ImaginAb Raises USD 21 Million In Series B Venture Financing 60

Transcend Medical Raises USD 22 Million In Series C Venture Financing 61

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 62

Wavetec Vision Systems Raises USD 0.8 Million In Venture Financing 63

Encore Vision Secures USD5 Million in Venture Funding 64

Wavetec Vision Raises USD 11 Million In Series D-2 Financing 65

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 66

Proteus Digital Health Raises USD 63 Million In Series F Financing Round 67

Health XL Raises Funds Through Venture Financing 68

Wavetec Vision Raises USD 16.5 Million In Venture Financing 69

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 70

ImaginAb Raises USD 12.5 Million In Series A Financing 71

WaveTec Vision Raises USD 1.5 Million In Venture Financing 72

Transcend Medical Secures USD16 Million in Series B Venture Funding 73

Private Equity 74

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 74

Partnerships 75

Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 75

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 76

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 77

Adamis Pharma Enters into Distribution Agreement with Sandoz 78

Pear Therapeutics Enters into Agreement with Sandoz 79

Pear Therapeutics Enters into Agreement with Novartis 80

NuvoAir Enters into Agreement with Novartis 81

Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 82

Propeller Health Enters into Agreement with Novartis Pharma 83

Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 84

Alcon Laboratories Enters Into Partnership Agreement with PowerVision 85

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 86

Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 87

Novartis Enters into Agreement with Microsoft 88

MedinCell Enters into Agreement with Sandoz International 89

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 90

CorTechs Labs Enters into Agreement with Novartis Pharma 91

Eveon Enters into Agreement with Advanced Accelerator Applications 92

Qiagen Enters into Co-Development Agreement with Novartis 93

SomaLogic Extends Co-Development Agreement with Novartis 94

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 95

Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 96

Foundation Medicine Extends Co-Development Agreement With Novartis 97

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 98

Sunovion Pharma Enters into Licensing Agreement with Novartis 99

BioQuiddity Expands Licensing Agreement with Sandoz 100

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 101

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 102

Life Technologies Enters Into Licensing Agreement With Novartis 103

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 104

Equity Offering 105

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 105

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 107

Debt Offering 109

Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 109

Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 110

Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 111

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 112

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 113

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 114

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 115

Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 116

Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 117

Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 118

Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 119

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For USD 1.5 Billion 120

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For USD 500 Million 121

Asset Transactions 122

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 122

Novartis Plans to Divest Assets of Alcon 123

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 124

Acquisition 126

GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 126

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 128

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 130

Alcon Acquires Transcend Medical 132

Novartis May Acquire Genfit 133

Novartis Acquires Ziarco Group 134

Novartis Acquires Encore Vision 135

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 136

Alcon Acquires WaveTec Vision Systems 137

Advanced Accelerator Applications Acquires Imaging Equipment 139

Advanced Accelerator Applications Acquires Barnatron 140

Advanced Accelerator Applications Acquires Catalana De Dispensacion 141

Novartis Acquires Vivacta For USD 90 Million 142

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 143

Novartis AG - Key Competitors 144

Novartis AG - Key Employees 145

Novartis AG - Locations And Subsidiaries 147

Head Office 147

Other Locations & Subsidiaries 147

Recent Developments 163

Strategy And Business Planning 163

Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 163

Financial Announcements 164

Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 164

Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 169

Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 173

Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 178

Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 183

Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 187

Corporate Communications 193

Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 193

May 16, 2018: Novartis announces changes to the Executive Committee 194

May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 195

Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 196

Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 197

Dec 15, 2017: Novartis announces Oncology head to retire 198

Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 199

Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 200

May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 201

Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 202

Government and Public Interest 203

Nov 28, 2017: Biosimilar drugs have the potential to save more than USD 54 billion 203

Product News 204

Jul 12, 2018: Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community 204

Jul 09, 2018: Microsoft and Partners Showcase a New 'Molecule' for Better Health Outcomes 205

Jul 06, 2018: Sandoz and its affiliate, Novartis Pharmaceuticals voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance 206

Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 208

Jun 06, 2017: Alcon highlights product and service innovations at 40th BCLA, one of the largest international meetings dedicated to contact lenses 209

Other Significant Developments 211

May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 211

Sep 29, 2017: Alcon flagship AcrySof intraocular lens reaches 100 million implants and counting 212

Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 213

Mar 16, 2017: Alcon and Orbis celebrate new Flying Eye Hospitalís visit to the UK 214

Mar 03, 2017: Alcon Launches New Digital Vision Care Marketing Portal for Eye Care Professionals 215

Mar 02, 2017: Alcon Supports Eye Health with Charitable Giving of Nearly $73 Million in 2016 and Renews Commitment to Think About Your Eyes 216

Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 217

Jan 26, 2017: Achievement of sales milestone for COPD products 218

Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 219

Appendix 220

Methodology 220

About GlobalData 220

Contact Us 220

Disclaimer 220

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

List of Tables

Novartis AG, Medical Equipment, Key Facts, 2017 2

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Deals By Market, 2012 to YTD 2018 13

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix for USD5 Million 24

Advanced Accelerator Applications to Acquire Two Production Sites in Germany 25

Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 26

SensoMotoric Sells Ophthalmic Division To Alcon Labs 27

Pear Therapeutics Raises USD50 Million in Series B Financing 28

ImaginAb Raises USD7.7 Million in Venture Financing 30

Rani Therapeutics Raises USD39 Million in Series D Financing 31

Lemonaid Health Raises USD11 Million in Series A Financing 33

Atlas Genetics Raises USD35 Million in Series D Financing 34

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 36

Rox Medical Raises USD40 Million in Series E Financing 38

Cota Raises Funds through Venture Financing 39

Rani Therapeutics Raises Funds in Financing 40

Ra Pharma Raises USD58.5 Million in Series B Financing 42

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 44

MyoPowers Medical Raises USD5 Million in Venture Financing 46

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 47

Autonomic Technologies Raises USD38 Million in Series D Financing 48

Merganser Biotech Raises USD28 Million in Series A Financing 50

Encore Vision Raises USD1 Million in Venture Financing 51

Atlas Genetics Raises USD20 Million in Series C Financing 52

Transcend Medical Raises USD7.2 Million in Venture Financing 54

BioNano Genomics Raises USD53 Million in Series C Venture Financing 55

Encore Vision Raises USD1.7 Million in Venture Financing 57

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 58

ImaginAb Raises USD 21 Million In Series B Venture Financing 60

Transcend Medical Raises USD 22 Million In Series C Venture Financing 61

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 62

Wavetec Vision Systems Raises USD 0.8 Million In Venture Financing 63

Encore Vision Secures USD5 Million in Venture Funding 64

Wavetec Vision Raises USD 11 Million In Series D-2 Financing 65

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 66

Proteus Digital Health Raises USD 63 Million In Series F Financing Round 67

Health XL Raises Funds Through Venture Financing 68

Wavetec Vision Raises USD 16.5 Million In Venture Financing 69

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 70

ImaginAb Raises USD 12.5 Million In Series A Financing 71

WaveTec Vision Raises USD 1.5 Million In Venture Financing 72

Transcend Medical Secures USD16 Million in Series B Venture Funding 73

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 74

Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 75

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 76

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 77

Adamis Pharma Enters into Distribution Agreement with Sandoz 78

Pear Therapeutics Enters into Agreement with Sandoz 79

Pear Therapeutics Enters into Agreement with Novartis 80

NuvoAir Enters into Agreement with Novartis 81

Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 82

Propeller Health Enters into Agreement with Novartis Pharma 83

Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 84

Alcon Laboratories Enters Into Partnership Agreement with PowerVision 85

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 86

Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 87

Novartis Enters into Agreement with Microsoft 88

MedinCell Enters into Agreement with Sandoz International 89

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 90

CorTechs Labs Enters into Agreement with Novartis Pharma 91

Eveon Enters into Agreement with Advanced Accelerator Applications 92

Qiagen Enters into Co-Development Agreement with Novartis 93

SomaLogic Extends Co-Development Agreement with Novartis 94

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 95

Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 96

Foundation Medicine Extends Co-Development Agreement With Novartis 97

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 98

Sunovion Pharma Enters into Licensing Agreement with Novartis 99

BioQuiddity Expands Licensing Agreement with Sandoz 100

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 101

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 102

Life Technologies Enters Into Licensing Agreement With Novartis 103

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 104

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 105

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 107

Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 109

Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 110

Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 111

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 112

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 113

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 114

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 115

Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 116

Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 117

Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 118

Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 119

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For USD 1.5 Billion 120

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For USD 500 Million 121

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 122

Novartis Plans to Divest Assets of Alcon 123

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 124

GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 126

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 128

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 130

Alcon Acquires Transcend Medical 132

Novartis May Acquire Genfit 133

Novartis Acquires Ziarco Group 134

Novartis Acquires Encore Vision 135

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 136

Alcon Acquires WaveTec Vision Systems 137

Advanced Accelerator Applications Acquires Imaging Equipment 139

Advanced Accelerator Applications Acquires Barnatron 140

Advanced Accelerator Applications Acquires Catalana De Dispensacion 141

Novartis Acquires Vivacta For USD 90 Million 142

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 143

Novartis AG, Key Competitors 144

Novartis AG, Key Employees 145

Novartis AG, Subsidiaries 147

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand